Global Organoids Market Overview
Organoids Market Size was valued at USD 2.6 Billion in 2022. The organoids market industry is projected to grow from USD 3.17 Billion in 2023 to USD 15.79 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.20% during the forecast period (2024 - 2032). Increasing demand for tumor modelling and bio banking and growing adoption of personalized drugs are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Organoids Market Trends
- Advancements in organoids technology is driving the market growth
One prominent trend in the organoids market revolves around continuous advancements in organoid technology. Researchers are consistently refining techniques for creating more complex and functional organoids that closely mimic the structure and function of human organs. These innovations enhance the reliability of organoids for disease modeling, drug testing, and personalized medicine applications. The trend underscores the industry's commitment to pushing the boundaries of organoid technology, offering more accurate and clinically relevant models for various biomedical research purposes. This factor drives market CAGR.
Additionally, an emerging trend in the organoids market involves the integration of Artificial Intelligence (AI) to enhance the analysis and interpretation of organoid data. As the complexity and scale of organoid experiments grow, AI algorithms play a crucial role in processing vast datasets, identifying patterns, and extracting meaningful insights. This trend not only accelerates the pace of research but also facilitates the identification of novel drug candidates and potential therapeutic interventions. The synergy between organoid technology and AI exemplifies a cutting-edge approach in advancing our understanding of organ development, disease mechanisms, and treatment strategies.
A significant trend in the organoids market is the increased application of organoids in disease modeling and drug discovery. Organoids provide a more physiologically relevant platform for studying diseases, enabling researchers to recreate intricate aspects of human organ function. This trend is particularly notable in cancer research, where organoids are used to model tumor behavior and test drug responses. The versatility of organoids extends to various organ systems, fostering breakthroughs in understanding diseases like neurodegenerative disorders and gastrointestinal conditions. The growing utilization of organoids in disease modeling and drug discovery reflects a transformative shift in the biomedical landscape, promising more effective and targeted therapeutic developments. For instance, in January 2021, BIOIVT partnered with Upcyte Technologies GmbH as the exclusive commercial worldwide distributor for its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).Thus, driving the organoids market revenue.
Organoids Market Segment Insights
Organoids Organ Type Insights
The organoids market segmentation, based on Organ Type includes Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, Others. The dominant category is brain, reflecting the substantial focus on developing brain organoids for studying neurological disorders, drug testing, and personalized medicine. The intricate nature of brain function and the prevalence of neurological diseases drive the dominance of this category. Meanwhile, the fastest-growing category is Lung, as there is an increasing emphasis on creating lung organoids for disease modeling, drug discovery, and understanding respiratory conditions.
Organoids Application Insights
The organoids market segmentation,based on Application, includes Development of Biology Disease, Pathology of infectious Disease, Regenerative Medicines, Drug Discovery, Personalized Medicine, Drug Toxicity, Efficacy Testing, Others. The dominant category is drug discovery, as organoids serve as highly relevant and predictive models for screening potential drug candidates, studying their effects on specific organs, and expediting the drug development process. The intricate three-dimensional structures of organoids closely mimic human tissues, providing a robust platform for assessing drug efficacy and safety. Meanwhile, the fastest-growing category is Regenerative Medicines, with an increasing focus on using organoids to develop therapies for tissue repair and regeneration.
Organoids Source Insights
The organoids market segmentation, based on Source, includes Pluripotent Stem Cell, Organ Specific Adult Stem Cell. The dominant category is pluripotent stem cell, as these cells possess the remarkable ability to differentiate into various cell types, allowing for the creation of organoids representing a wide array of tissues. On the other hand, the fastest-growing category is Organ-Specific Adult Stem Cell-derived organoids, driven by the increasing emphasis on maintaining organotypic characteristics and functionality. Organ-Specific Adult Stem Cells are sourced directly from the targeted organs, enhancing the physiological relevance of organoids and supporting applications such as drug testing and regenerative medicine.
Organoids Type Insights
The organoids market segmentation, based on Type, includes Instruments, Consumables, and Services. The dominant category is consumables, encompassing culture media, reagents, and other essential supplies crucial for the maintenance and growth of organoids. The high demand for consumables is propelled by the continuous need for specialized materials in organoid culture and experimentation, making it a cornerstone of the market. Meanwhile, the fastest-growing category is Services, reflecting the increasing reliance on outsourced expertise for organoid generation, maintenance, and analysis. As the complexity of organoid technology expands, organizations seek specialized services to navigate intricate processes and ensure optimal outcomes in their research or drug development endeavors.
Figure1: Organoids Market, by Type, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Organoids Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American organoids market area will dominate this market, owing to the boasts a robust biomedical research landscape with numerous renowned academic institutions, research centers, and pharmaceutical companies actively engaged in cutting-edge research and development. In addition, the growing number of establishing health clubs and fitness facilities will boost market growth in this region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure2: ORGANOIDS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe organoids market accounts for the second-largest market share due to the robust scientific community and a wealth of leading research institutions and universities actively contributing to advancements in organoid technology. Further, the German organoids market held the largest market share, and the UK organoids market was the fastest growing market in the European region
The Asia-Pacific Organoids Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to increased investments in healthcare and research infrastructure. Moreover, China’s organoids market held the largest market share, and the Indian organoids market was the fastest growing market in the Asia-Pacific region.
Organoids Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the organoids market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, organoids industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the organoids industry to benefit clients and increase the market sector. In recent years, the organoidsindustry has offered some of the most significant advantages. Major players in the organoids market, including STEMCELL Technologies, Inc., Cellesce Ltd, Hubrecht Organoid Technology, Definigen, 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences), Merck KGgA, and others, are attempting to increase market demand by investing in research and development operations.
Utrecht Organoid Technology (HUB) is a biotechnology company specializing in the development and application of advanced organoid technology. Headquartered in Utrecht, Netherlands, HUB focuses on creating innovative three-dimensional organoid models that closely mimic the complexity of human organs. Ubrecht Organoid Technology (HUB) and BGI-Qingdao announced that they have signed a Memorandum of Understanding (MoU) to form a collaboration to establish a joint Next Generation Diagnostics (NGD) center to improve personalized care, better treatments, and cure as well as faster development of new safe medicines in China.
Cellesce Ltd. is a biotechnology company based in Cardiff, United Kingdom, specializing in the field of organoid technology. Founded in 2016, Cellesce is at the forefront of developing innovative and patient-specific organoids for biomedical research and drug discovery. Cellesce Ltd. announced the impending arrival of new patient-derived Breast Cancer organoid lines. These new lines have been fully validated for compatibility with their proprietary organoid expansion process.
Key Companies in the organoids market include
Organoids Industry Developments
May 2023: Next&Bio Inc., a company that established an organoid-based precise medicinal search and development framework, has inked an agreement of understanding (MOU) with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) on the establishment of a joint venture to realize the advancement of innovative accuracy medicine treatments using cancer-organoids.
August 2021: STEMCELL Technologies, which is a based company, and Hubrecht Organoid Technology (HUB) signed a contract to use tissue-derived organoids-including lung, liver, and intestinal organoids— in preclinical toxicology screening as well as for non-cancer drug development services that are offered by the Contract Assay Services, which is part of STEMCELL company.
Organoids Market Segmentation
Organoids Organ Type Outlook
- Intestine
- Liver
- Stomach
- Pancreas
- Lung
- Brain
- Kidney
- Others
Organoids Application Outlook
- Development of Biology Disease
- Pathology of infectious Disease
- Regenerative Medicines
- Drug Discovery
- Personalized Medicine
- Drug Toxicity
- Efficacy Testing
- Others
Organoids Source Outlook
- Pluripotent Stem Cell
- Organ Specific Adult Stem Cell
Organoids Type Outlook
- Instruments
- Consumables
- Services
Organoids Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size2022 |
USD 2.6Billion |
| Market Size 2023 |
USD 3.17Billion |
| Market Size2032 |
USD 15.79Billion |
| Compound Annual Growth Rate (CAGR) |
22.20%(2023-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Organ Type, Application, Source, Type and Region |
| Geographies Covered |
North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered |
The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
 STEMCELL Technologies, Inc., Cellesce Ltd, Hubrecht Organoid Technology, Definigen, 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences),Merck KGgA |
| Key Market Opportunities |
·      Increasing Demand for Tumor Modelling and Bio banking |
| Key Market Dynamics |
·      growing adoption of personalized drugs |
Frequently Asked Questions (FAQ) :
The organoids market size was valued at USD 2.6Billion in 2022.
The global market is projected to grow at a CAGR of 22.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are STEMCELL Technologies, Inc., Cellesce Ltd, Hubrecht Organoid Technology,Definigen,3Dnamics, Inc., Organoid Therapeutics ,PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences),Merck KGgA.
The Brain category dominated the market in 2022.
The Drug Discovery based had the largest share in the global market.
